

GP 1804

0300

18H1

0150

2-7-95

LOC
0150

2-17-95

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Stewart D. Lyman and
M. Patricia Beckmann

Serial No.: 08/243,545

Filed: May 11, 1994

For: LIGANDS FOR FLT3 RECEPTORS



Attorney Docket No. : 2813-E

Group Art Unit: 1812

Examiner: L. Spector

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Dear Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, applicants hereby provide copies of the documents listed on the attached Form PTO-1449.

US Patent 5,185,438 (Lemischka-1) describes the cloning and characterization of the murine flk-2 receptor.

US Patent 5,270,458 (Lemischka-2) describes the cloning and characterization of the murine flk-2 receptor.

US Patent No. 5,116,964 describes the fusion molecules comprising murine LHR: IgG or LHR:IgG:CD4:IgG.

Documents A and B describe the basic characteristics of growth factor receptor tyrosine kinases ("RTKs"), and are cited in the Background section of the instant application.

Document C describes a mononuclear phagocyte growth factor termed "CSF-1."

Document D describes the isolation and sequence information of the murine flt-3 receptor.

Document E describes the isolation of a RTK called murine "flk-2."

Document F describes the comparison of murine flt-3 receptor of Document D to the murine flk-2 receptor of Document E. Certain differences are noted.

Document G describes the isolation of the murine flt-3 receptor.

Document H describes the molecular cloning and isolation and characterization of the ligand for the flt3- receptor. The inventors of the instant application are named authors.

Document I describes the characterization and tissue distribution of the murine flt-3 receptor.


Document J describes the expression of flt-3 receptors in human acute leukemias.

Document K describes the isolation of the human homologue to the murine flk-2 receptor, that the authors termed "STK-1."

Document L describes the CSF-1 stimulation of cells transformed with the murine flk-2/flt-3 receptor gene.

Since the submission of the above documents is made before the mailing of the first Office Action in connection with the above-captioned application, no fee under 37 CFR 1.17(p) is believed necessary. However, should a fee be required, applicants authorize the Commissioner to charge Deposit Account No. 09-0089 in an amount necessary to permit the consideration of this Information Disclosure Statement.

Respectfully submitted,




Stephen L. Malaska
Attorney for Applicants
Reg. No. 32, 655

Immunex Corporation
Legal Affairs Department
51 University Street
Seattle, WA 98101
Telephone: (206) 587-0430

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks,

Washington, D.C. 20231 on December 20, 1994


(Signature)